# Retrospective Analysis of Regorafenib Efficiency in Treatment of Metastatic Colorectal Cancer—Experience of Two Polish Comprehensive Cancer Centers

## TL;DR

This study evaluated regorafenib's effectiveness in treating advanced colorectal cancer patients in Poland, finding similar results to previous trials but highlighting the need for better treatment strategies.

## Contribution

The study provides real-world evidence of regorafenib's efficacy in a Polish patient cohort, emphasizing variability in outcomes and the need for personalized treatment strategies.

## Key findings

- Median progression-free survival was 2.5 months and median overall survival was 5.8 months.
- Disease stabilization was observed in five patients with a median duration of 5.6 months.
- Results were comparable to the phase III CORRECT trial, with minor differences likely due to patient variability.

## Abstract

Objectives: Colorectal cancer is a major public health concern, ranking third in incidence among all malignant tumors both in Poland and globally. We conducted a retrospective study to evaluate the effectiveness of regorafenib in patients with metastatic colorectal cancer ineligible for local therapy treated at two Polish comprehensive cancer centers between 2021 and 2024. Methods: The analysis included 29 patients who had previously received all standard therapies: fluoropyrimidines, oxaliplatin, and irinotecan (in a multi-agent regimen or sequentially) and bevacizumab (anti-VEGF therapy). In patients with tumors negative for KRAS, NRAS and BRAF mutations, cetuximab or panitumumab (anti-EGFR therapy) were also used. Results: The median progression-free survival (PFS) was 2.5 months, and the median overall survival (OS) was 5.8 months. Disease stabilization was observed in five patients, with a median duration of 5.6 months, and no partial or complete remission were recorded. Conclusions: Our results were similar to those of the phase III CORRECT trial, which established the clinical utility of regorafenib. Only minor differences in survival outcomes were noted—likely due to real-world variability in patient characteristics and timing of treatment assessments. However, continued investigation of personalized and sequential treatment strategies that contain anti-angiogenic drugs is warranted to optimize outcomes.